With over 0.47 million Rhythm Pharmaceuticals Inc. (RYTM) shares trading Friday and a closing price of $40.68 on the day, the dollar volume was approximately $19.1 million. The shares have shown a positive half year performance of 155.37% and its price on 01/12/24 lost nearly -2.00%. Currently, there are 56.61M common shares owned by the public and among those 51.55M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 9 analysts who have offered their price forecasts for RYTM have a consensus price objective of $52.67. The analysts have set the share’s price value over the next 12 months at a high of $70.00 and a low of $42.00. The average price target is 22.76% above its recent price level and an upside to the estimated low will see the stock gain 3.14% over that period. But an upside of 41.89% will see the stock hit the forecast high price target while median target price for the stock is $50.00.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 52 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 23 of these insider trades were purchases, accounting for 115,596 shares. Insider sales of the common stock occurred on 29 occasions, with total insider shares sold totaling 100,589 shares.
Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) opened at $42.77, up $1.26 from a prior closing price of $41.51. However, the script later moved the day high at 43.40, down -2.00%. The company’s stock has a 5-day price change of 2.34% and 67.75% over the past three months. RYTM shares are trading -11.51% year to date (YTD), with the 12-month market performance up to 33.64% higher. It has a 12-month low price of $15.50 and touched a high of $50.28 over the same period. RYTM has an average intraday trading volume of 727.94K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.88%, 9.92%, and 65.00% respectively.
Institutional ownership of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) shares accounts for 105.08% of the company’s 56.61M shares outstanding.
It has a market capitalization of $2.40B and a beta (3y monthly) value of 1.95. The earnings-per-share (ttm) stands at -$3.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.82% over the week and 6.26% over the month.
Analysts forecast that Rhythm Pharmaceuticals Inc. (RYTM) will achieve an EPS of $Rhythm Pharmaceuticals, Inc. for the current quarter, $40.68 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Rayonier Advanced Materials Inc while analysts give the company a high EPS estimate of $Invesco S&P 500 Equal Weight Te. Comparatively, EPS for the current quarter was $ROYAL MINES & MINERALS CORP a year ago. Earnings per share for the fiscal year are expected to increase by 8.07%, and 23.51% over the next financial year. EPS should shrink at an annualized rate of -9.00% over the next five years, compared to -4.19% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate Rhythm Pharmaceuticals Inc. (RYTM) as a “Strong Buy” at a consensus score of 1.00. Specifically, 9 Wall Street analysts polled rate the stock as a buy, while 0 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the RYTM, a number of firms have released research notes about the stock. Morgan Stanley stated their Overweight rating for the stock in a research note on December 19, 2023, with the firm’s price target at $29-$55.
